0.42
-0.01(-2.32%)
Currency In USD
| Previous Close | 0.43 |
| Open | 0.43 |
| Day High | 0.44 |
| Day Low | 0.4 |
| 52-Week High | 2.64 |
| 52-Week Low | 0.37 |
| Volume | 4.86M |
| Average Volume | 4.59M |
| Market Cap | 4.04M |
| PE | -0.1 |
| EPS | -4.22 |
| Moving Average 50 Days | 0.43 |
| Moving Average 200 Days | 0.85 |
| Change | -0.01 |
If you invested $1000 in Theriva Biologics, Inc. (TOVX) 10 years ago, it would be worth $0.02 as of October 19, 2025 at a share price of $0.421. Whereas If you bought $1000 worth of Theriva Biologics, Inc. (TOVX) shares 5 years ago, it would be worth $5.18 as of October 19, 2025 at a share price of $0.421.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 16, 2025 12:11 PM GMT
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high un
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
GlobeNewswire Inc.
Oct 13, 2025 12:00 PM GMT
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
GlobeNewswire Inc.
Oct 06, 2025 12:00 PM GMT
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects - - Pre-ESGCT meeting monograph includes preclinical data de